Market Research Logo
Region: Africa
Category: Pharmaceuticals

Africa Pharmaceuticals

(312 reports matching your criteria)
  • Ghana Pharmaceuticals & Healthcare Q1 2019

    ... has led to difficulties doingbusiness, including high operational costs for foreign companies. While Ghana is positioned as one of the more attractivepharmaceutical markets for multinational firms on a regional basis, generic products will maintain a ... Read More

  • Mozambique Pharmaceuticals & Healthcare Q1 2019

    ... to deter any meaningful investmentfrom multinational drugmakers. Although growth will remain positive over our forecast (in local currency terms), the market willremain one of the least attractive in Sub-Saharan Africa, weighed down further by extremely ... Read More

  • Tunisia Pharmaceuticals & Healthcare Q1 2019

    ... will challenge foreign investment into the sector.Highlighting the market's longer-term potential, some multinational drugmakers have shown their willingness to do business in thecountry, though the majority choose to operate indirectly to minimise the risks involved. Read More

  • OTC Medications in South Africa (2018) – Market Sizes

    ... excludes all other OTC products and those which require prescriptions but includes pharmacy approved. Supplements are excluded unless they are combined with vitamins/medicines and these form a main selling point; or marketed solely as remedies ... Read More

  • Vitamins & Minerals in South Africa (2018) – Market Sizes

    ... and/or minerals form a main selling point are also included, but excluded are those supplements where vitamins are naturally intrinsic to one of the ingredients . It excludes products which require prescriptions but includes pharmacy ... Read More

  • Nigeria Pharmaceuticals & Healthcare Q1 2019

    ... despite it's elevatedrisk profile. Long-term opportunities are supported by robust fundamentals such as a large market size and expandingpopulation. The implementation of governmental initiatives aims to drive growth in the sector over the coming years. Read More

  • Mauritius Pharmaceuticals & Healthcare Q1 2019

    ... will translate into growing pharmaceuticalsales. However, Mauritius’s small pharmaceutical market size will continue to limit drugmaker opportunities. The island's transitiontowards becoming a transhipment and financial hub for Sino-African trade will benefit health industries development over ... Read More

  • Cote d'Ivoire Pharmaceuticals & Healthcare Q1 2019

    ... experience growth through 2019 as production rampsup from several large new offshore fields. The monetisation of the country's gas resources remains largely contingent on plans for aFLNG export terminal, the timeline for which remains unclear. Read More

  • Zambia Pharmaceuticals & Healthcare Q1 2019

    ... will continue to deter innovativedrugmakers from involvement in the market. Still, opportunities for low-cost generic medicines remain plentiful, especially given thehigh burden of communicable conditions and the need to deal with outbreaks of viral diseases. Read More

  • Egypt Pharmaceuticals & Healthcare Q1 2019

    ... a new drug authority in Egypt will improve the medicine regulatory environment. Risks in the form ofdelays to implementation and macroeconomic challenges will persist. Pharmaceutical market growth remains on a robusttrajectory, outperforming the MENA average. Read More

  • Ethiopia Pharmaceuticals & Healthcare Q1 2019

    ... through subsidised health insuranceschemes, and authorities' support for pharmaceutical investment are just some of the factors that would provide a fertile ground forsubstantial volume and value growth. On the other, this potential will mostly attract ... Read More

  • South Africa Pharmaceuticals & Healthcare Q1 2019

    ... status for innovative medicine launches. Nevertheless, South Africa’sconsiderable market size leaves it exposed to a number of external influences, both industry and macroeconomic related. Keydevelopments to watch over the near term include the impact of ... Read More

  • Angola Pharmaceuticals & Healthcare Q1 2019

    ... will be driven the country’s growing disease burden andincreasing population. However, given the low levels of affordability, poor access to healthcare, and relatively young age of itspopulation, the market will mainly be suited to generic ... Read More

  • Sub-Saharan Africa Pharmaceuticals & Healthcare Q4 2018

    ... within the generic medicines sector, while the larger, moredeveloped markets present viable opportunities for patented medicine sales in urban regions. Cooperative agreements withinternational firms will provide opportunities for domestic firms to expand their manufacturing capacities. Read More

  • Algeria Pharmaceuticals & Healthcare Q1 2019

    ... and healthcare industries willcontinue to create investment opportunities, despite the slow progress in improving the regulatory environment. Despite sustaineddevelopment of local drug manufacturing capacity - which is in part driven by foreign direct investment and ... Read More

  • Cameroon Pharmaceuticals & Healthcare Q1 2019

    ... Although the health system and pharmaceutical sector willcontinue to gradually develop, low spending per capita on medicine and a poor operating environment will continue to weigh onopportunities presented to drugmakers in the short term. The ... Read More

  • Kenya Pharmaceuticals & Healthcare Q1 2019

    ... or distributors. Authorities are also investing in regulatoryimprovement initiatives, which will complement their efforts to achieve universal healthcare coverage. On the other hand, someforeign players may remain weary of committing to the market due to ... Read More

  • Uganda Pharmaceuticals & Healthcare Q4 2018

    ... remain dominant, while the government plans to localisedrug production to boost medicine sustainability. While the market has brighter long-term prospects, multinational drugmakerappetite will remain subdued despite the positive economic growth forecast over the coming years. Read More

  • Zimbabwe Pharmaceuticals & Healthcare Q4 2018

    ... multinational drugmakers are deterred by thechallenging macroeconomic environment. Achieving self-sufficiency in the sector will require currency regime reform; however, itremains unclear which new regime they will adopt. This creates uncertain conditions in Zimbabwe's pharmaceutical market ... Read More

  • Namibia Pharmaceuticals & Healthcare Q4 2018

    ... and efficiency issues within the public healthcare sector. The small middle-and upper-class segments provide pockets of demand for innovative medicines, which will continue to be imported by key regionalplayers and representative offices of established multinationals. Read More

  • Gabon Pharmaceuticals & Healthcare Q4 2018

    ... by factors including modest but growingpopulation numbers, high prevalence of infectious diseases and the growing burden of civilisation diseases. However, given thetight funding environment, most of the commercial opportunities remain limited to the generics sector. Read More

  • Botswana Pharmaceuticals & Healthcare Q4 2018

    ... healthcare. Medicine sales will be limited by weakregulatory framework, a small pensionable population and a highly ruralised community. Despite a potential for growth in theunderdeveloped sector, multinational drugmakers will favour larger markets in the region ... Read More

  • Morocco Pharmaceuticals & Healthcare Q4 2018

    ... treatments. Although the government'scommitment to improving healthcare via the expansion of health insurance coverage will be a significant factor for future medicinesales growth, we believe generics drugmakers will be the main beneficiaries as the state ... Read More

  • Tanzania Pharmaceuticals & Healthcare Q4 2018

    ... limited by low per capita spending on medicines andan underdeveloped healthcare sector. Whilst demand for medicine will increase over the long-term, driven by the country’s rapidlyexpanding population and high disease burden, we expect that Tanzania's ... Read More

  • Sudan and South Sudan Pharmaceuticals & Healthcare Q4 2018

    ... of commercial incentives limit multinational drugmaker interest in the market.Positive fundamentals in the form of a rising chronic disease burden and large population bode well for long-term opportunities,however, the elevated industry-and-operational risks will undermine any ... Read More

< prev 1 3 4 5 6 7 8 9 10